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Abstract
Aminoacyl-tRNA synthetases (ARSs) and ARS-interacting multifunctional proteins (AIMPs) exhibit remarkable functional
versatility beyond their catalytic activities in protein synthesis. Their non-canonical functions have been pathologically
linked to cancers. Here we described our integrative genome-wide analysis of ARSs to show cancer-associated activities in
glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor. We first selected 23 ARS/AIMPs
(together referred to as ARSN), 124 cancer-associated druggable target genes (DTGs) and 404 protein-protein interactors
(PPIs) of ARSs using NCI’s cancer gene index. 254 GBM affymetrix microarray data in The Cancer Genome Atlas (TCGA) were
used to identify the probe sets whose expression were most strongly correlated with survival (Kaplan-Meier plots versus
survival times, log-rank t-test ,0.05). The analysis identified 122 probe sets as survival signatures, including 5 of ARSN
(VARS, QARS, CARS, NARS, FARS), and 115 of DTGs and PPIs (PARD3, RXRB, ATP5C1, HSP90AA1, CD44, THRA, TRAF2, KRT10,
MED12, etc). Of note, 61 survival-related probes were differentially expressed in three different prognosis subgroups in GBM
patients and showed correlation with established prognosis markers such as age and phenotypic molecular signatures.
CARS and FARS also showed significantly higher association with different molecular networks in GBM patients. Taken
together, our findings demonstrate evidence for an ARSN biology-dominant contribution in the biology of GBM.
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Introduction
Mammalian aminoacyl-tRNA synthetases (ARSs) and ARS-
interacting multifunctional proteins (AIMPs) carry out the first
step of protein synthesis by catalyzing the ligation of amino
acids to their cognate tRNAs. However, they also contain other
domains unrelated to catalytic activities to form diverse
complexes with each other or with other cellular regulatory
factors. This structural complexity seems to be linked to
a functional versatility, and their expanded functions have been
implicated in a variety of human diseases including cancers [1].
Several ARSs have been shown to be abnormally up- or down-
regulated in hepatomas, colon cancer, Burkett’s lymphoma,
prostate adenocarcinoma, breast cancer, sarcoma, colorectal
adenocarcinoma and pituitary adenoma [2–5]. In addition, the
functional regulation of cell growth, differentiation, RNA
splicing, cytokine activities, and angiogenesis by ARSs in
various disease states such as breast cancer, colon cancer,
prostate cancer, and renal cell cancer has been studied [6–10].
Overexpression of MRS was also reported in malignant fibrous
histiocytomas, sarcomas, malignant gliomas and glioblastomas
[1]. These tumors have amplification of the chromosome 12q13
locus, where the gene for MRS overlaps with the gene for
CHOP, which functions as an inhibitor of C/EBP12. This
amplification probably results in the overexpression of MRS and
CHOP, which may promote a favorable milieu for tumor
progression [11]. However, despite that ARSs have been linked
to human cancers, their biological significance is still not
completely understood.
Here we described our integrative genome-wide analysis of
ARSs to show cancer-associated regulatory activities with an
emphasis on glioblastoma multiforme (GBM) [12] using NCI’s
cancer gene index (CGI) [13] and The Cancer Genome Atlas
(TCGA) database [14]. First, we selected 23 ARS/AIMPs
(ARSN), 124 cancer-associated druggable target geneset (DTG)
and 404 protein-protein interactors (PPIs) of ARSs. Then, we
assigned each of the geneset to several prognostic molecular
signatures of GBM (GEO accession #GSE4271) including
proneural (PN), proliferative (Prolif) and mesenchymal (Mes)
[15] and identified survival-related genes that are differentially
expressed among samples in each subtype compared to other
subtypes. We showed several candidates that are more likely to
interact with aminoacyl-tRNA synthetase and their different
involvement in each specific subtype. Thus, our study suggests
potential contribution of ARSs with their PPI gene sets on the
phenotype of GBM.
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Results
ARSN Shows Potentially Association with Cancers
through Interactions with DTGs
To examine the potential association of ARS family with cancer
at a systemic level, we compared the expression profiles of the
genes encoding the 20 human cytoplasmic ARSs and AIMP1–3
(AIMPs) with those of known DTGs obtained from the US
National Cancer Institute’s cancer gene index (CGI). Detailed
analysis procedures are outlined in Figure 1. We selected 124
DTGs that can interact with 23 ARS/AIMPs, and 404 genes as
protein-protein interactors of ARSs. For the comparison, we also
selected 1874 non-cancer-associated genes (nonCAGs) (each
geneset is detailed in Table S1). In the first example from the
CGI, the genesets were used to show cancer-associated regulatory
activities with Cytoscape. We categorized the data into ten cancer
groups (brain, colon, kidney, cervix, haematopoietic and lym-
phoid, liver, prostate, lung, breast, and gastric cancer).
Using the cancer-associated interactions between ARSs and
AIMPs, and three genesets, as expected, a large number of the line
based on the node of ARSN-DTGs indicates higher association
between ARSN and DTGs than ARSN-PPIs (Figures S1, S2, S3,
S4). A cancer-association map was also established to display how
much ARSs and AIMPs could be differently interacted to ten
different cancers (Figures S5, S6, S7, S8, S9, S10, S11, S12, S13,
S14). Four large cancer sets connected to components of the
cancer association interaction network were shown in Figure 2.
The cancer node size indicates the number of interactions with the
brown node gene. Among the components of ARSN, relatively
higher cancer-associated network was shown by GARS, MARS,
WARS, RARS, CARS, AIMP1 (SCYE1) and AIMP3 (EEF1E1)
(green nodes). Also, AIMP1, MARS, and RARS have relatively
higher association with cancers, indicating their potential impor-
tance in cancer biology and the needs of pathological mechanistic
studies.
Figure 1. Outline of analysis procedures with each geneset showing the general steps required to identify genes that modulate
a specific phenotype: selection of genes with the desired phenotype, and identification of phenotype-inducing ARSN and
corresponding cancer-associated druggable target genes.
doi:10.1371/journal.pone.0040960.g001
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Correlation Map Signatures Define ARSN Subclasses of
Glioblastoma
For cancer-associated systematic analyses of ARSs and AIMPs,
we applied the genesets to the 254 GBM affymetrix U133plus2
microarray dataset in the TCGA. In this dataset, we identified 846
resulting probe sets including 168 DTGs and 678 PPIs that can
directly interact with ARSs and AIMP1–3. For comparison, we
also selected 978 probe sets among 1874 nonCAGs (each probeset
is detailed in Table S2). To understand ARSN interactions with
each DTGs/PPIs/nonCAGs and visualize the relationship
between the genesets, a correlation map was made. First, the
DTGs probeset was clustered on the basis of Pearson correlation
coefficients that related their expression patterns across the 254
GBM tissues to the expression patterns of ARSN over the same
tissue set, as shown in Figure 3a. We then clustered PPIs and
nonCAGs on the basis of these correlation coefficients. In this
analysis, a red color indicates that two genes tend to be up or
down-regulated together (positively); a blue color indicates the
opposite tendency (negatively). The clustered map of the geneset-
geneset correlation showed a relatively positive or negative
correlation between two gene sets. For the three interaction sets
in which the correlation coefficient rule for more than 0.4
performed significantly, we investigated the frequency of more
than 0.4 to determine if any set had relatively high frequencies of
significant correlation. The frequency histograms was shown in
Figure S15. For the ARSN-DTG set, the correlation coefficient
more than 0.4 had a relatively high frequency of 0.35% versus
0.51% of the ARSN-PPI. For the ARSN-nonCAG set, a relatively
low frequency of 0.09% was shown. Also, the differences in the
median values among the sets are statistically significant (P,0.001,
one-way ANOVA).
To clearly understand molecular interactions of each geneset,
we performed supervised hierarchical clustering analyses using the
map, showing that three clusters lead to a low false discovery rate
(FDR ,0.005), thus appears to provide significant interactive
specificities of each cluster (Figure 3b). ARSN were shared by
three groups. The first ARSN subgroup appears to be closely
related to DTGs. We identified that several ARSN such as WARS,
RARS, and AIMP1 showed a highly significant association with
31 DTG genes (Table S3) (positive association with 21 DTGs and
Figure 2. Cancer-associated interactions between 23 ARSs and AIMPs, and three genesets. 3501 genes were selected by manual curation,
clinical examination and causal relationship to cancer. Using 11 public database showing the curated interactions of human proteins (HPRD, BioGRID,
KEGG, Reactome, BIND, MINT, IntAct, InnateDB, DIP, STRING, and PharmDB), we further selected 124 DTGs and 404 genes as PPIs of ARSs. Using
a cancer-associated interactions analysis, a cancer-association map was established to display how much ARSs and AIMPs could be differently
interacted to ten different cancers. Each brown node indicates each gene of respective cancer and each node size indicates the degree of cancer-
dependent co-association of a gene. Line indicates the co-association between ten cancers and seven ARSN. The cancer node size indicates the
number of interactions with the brown node gene. Seven components of ARSN (green nodes) show relatively higher cancer-associated network.
doi:10.1371/journal.pone.0040960.g002
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negative association with 10 DTGs), suggesting their potential
contribution to the GBM biology. The second subgroup includes
11 ARSN (EPRS, VARS, NARS, LARS, FARS, KARS, YARS,
MARS, AIMP3, and AIMP2) and showed reversed biological
functions with 31 DTGs compared to the first group. However,
the third group including 9 ARSN (AARS, DARS, SARS, GARS,
IARS, TARS, QARS, HARS, and CARS) showed relatively low
correlation coefficients. Current microarray data clustering
methods are limited to linear association between individual gene
expression values and phenotype. To understand nonlinear
associations between gene expression and phenotype that may
not be linear associations, we used a quantitative (numeric) trait
analysis in which we could make relationships based on nonlinear
association between two gene expression sets. This method is
a useful tool for detecting gene classes correlated with a quantita-
tive trait and to explore the patterns of gene-class association. In
this analysis, 16 DTGs (Table S4) were correlated with three
subgroups of ARSN (Figure 3c, P,0.05). The results of two
association methods showed the same number of cluster with the
similar trends of the associations. 9 DTGs (UBE2I, KRAS,
MARCKS, NFKB1, NR3C1, TP53, VKORC1, YY1, and HLA–
B) were overlapped for the linear and nonlinear associations. On
the other hand, 4 genes (NF1, CYP1A2, TGFB2, and CTGF)
were not detected as differentially interacted with ARSN by the
linear association method. However, we couldn’t show if the
nonlinear profiles reflect the general trends of the associations, so
further studies are needed. A comparative analysis of the
association pattern between the PPIs and the individual ARSN
was shown in Figure S16 and S17. In this case, ARSN were shared
by two groups, showing a highly positive and negative association
with 119 PPI genes. But it showed a low false discovery rate (FDR
,0.014, thus appears to provide weak interactive specificities of
Figure 3. Correlation patterns of 23 ARSs and AIMPs to three different genesets. (a) We identified 846 resulting probe sets including 168
DTGs and 678 PPIs that can directly interact with ARSN using 254 GBM affymetrix U133plus2 microarray dataset in TCGA. For the comparison, we also
selected 978 probe sets among 1874 nonCAGs. To understand ARSN-DTGs/PPIs/nonCAGs interactions and visualize the relationship between
genesets, a correlation map was made on the basis of their correlation levels with each set. The probe sets are presented in matrix format, where
rows represent individual genes of DTGs, PPIs, and nonCAGs, respectively, and columns represent each gene of ARSN. Each cell in the matrix
represents the correlation level of a gene in an ARSN. Red color indicates that the gene tends to be up or down-regulated together; Blue color
indicates the opposite tendency (The darker, the stronger the association between two genes). (b) Hierarchical clustering analysis showed that ARSN
were shared by three groups with 31 DTGs (FDR ,0.005). 31 DTGs were generated on a supervised hierarchical clustering analysis. (c) Hierarchical
clustering of ARSN based on the 16 DTGs based on nonlinear association between two gene expression sets. 16 DTGs were correlated with three
subgroups of ARSN.
doi:10.1371/journal.pone.0040960.g003
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PPI as compared to DTGs. The nonlinear association analysis also
showed two groups of ARSN having a highly significant
association with 117 PPI genes. Taken together, these results
indicated that ARSNs suggest possible mechanisms and processes
involved in the DTGs regulation.
ARSN Expression and Correlation with Survival in Patients
with GBM
To identify gene expression patterns that classify GBM tumors
into ARSN biology-dominant groups, we used 846 probe sets as
described previously. We first identified probe sets whose
expression most strongly correlated with survival (Kaplan-Meier
plots versus survival times, log-rank t-test ,0.05). This analysis
identified that 122 resulting probe sets of ARSN (VARS, QARS,
CARS, NARS, FARS), DTGs (PDE4A, NF1, NBN, CETP,
SMAD3, HIST3H2A, TFRC, PTPRC, MTAP, etc), and PPIs
(PARD3, RXRB, ATP5C1, HSP90AA1, CD44, THRA, TRAF2,
KRT10, MED12, etc) that were correlated with survival in
patients with GBM (Table S5). The effect of several genes
expressions on survival was shown in Figures S18, S19, S20. Then,
we performed a supervised clustering with the 122 probesets and
GBM samples (GEO accession #GSE4271) showing well-known
glioblastoma subtypes such as Proneural (PN; median survival of
the PN subclass is 174.5 weeks), Proliferative (Prolif; 60.5 weeks)
and Mesenchymal (Mes; 65.0 weeks) [15]. As shown in Figure 4a,
this analysis showed that 61 probe sets among 122 probe sets were
differentially expressed in the three discrete subgroups based on
the statistical cut-off (P = 0.01), including CARS and FARS, and
59 probe sets (Table S6). Using 61 probeset as a signature, the PN
subtype showed a dominant feature of expression pattern of the
gene sets compared to Prolif and Mes subtypes, suggesting
consistent prediction patterns by a 61 probe set expression
signature. To determine whether CARS and FARS contribute
to differences in biological characteristics of GBM tumors, we
examined expression of two ARSs. As shown in Figure 4b, CARS
was overexpressed in Prolif and Mes subtypes, while FARS was
overexpressed in PN subtype. Kaplan-Meier plots and log-rank
survival analyses showed that the median overall survival time of
under-expressed CARS group was longer (66.9 weeks) than that of
over-expressed group (51.4 weeks). Also, the median overall
survival time of over-expressed FARS group was longer (59.2
weeks) than that of under-expressed group (50.0 weeks).
To search the expression of the 61 probe sets in normal brain
tissues, we assessed the probe sets’ expression signatures with other
independent public GBM gene expression datasets (e.g., GSE4290
dataset) [16]. In the GSE4290 dataset, the expression levels of the
61 probe sets were different between a set of non-tumors and
GBM tumors (Figure 4c). CARS was overexpressed in the GBM
tumors, while FARS was not significantly overexpressed in either
tissue. Of interest, in the GSE4290 datasets for astrocytomas (II
and III) and oligodendrogliomas (II and III), no correlations were
identified with the 61 probe sets (Figures S21, S22, S23),
suggesting that the 61 probe set signature was specific for GBM.
CARS and FARS Correlations with different Molecular
Networks in Patients with GBM
To investigate if there is any difference in the interaction
networks of CARS and FARS in the three subtypes, we selected 48
genes (Table S7) that can directly interact with CARS and FARS
using our previously published data [1]. Then, we performed
a supervised clustering with the 48 genes and GBM samples (GEO
accession #GSE4271). As shown in Figure 5a, this analysis
showed that 24 probes (16 genes) among 48 genes were
differentially expressed in the three discrete subgroups
(P= 0.001). In Figure 5b, several interactors, such as PACSIN2
and SMAD9, were overexpressed PN subtype, while HNRNPR
and GMPS were overexpressed in Prolif subtype. Using 16 genes
as a molecular interaction signature of CARS and FARS, the PN
subtype showed a different feature of expression pattern of each
interactor compared to Prolif and Mes subtypes, suggesting
different interaction patterns of the two ARSs in each subtype.
To detect the differences in the functional profiles, we placed
differentially expressed genes in the context of present interactome
knowledge, using the Ingenuity Pathways Analysis tools (P for all
,0.05), showing that RNA metabolic process (FARSB, SMAD9,
FARS2, MAPK3, HNRNPR, and RARS) was significantly related
with PN and Prolif subtypes. Significantly up-regulated molecular
functions for PN subtype was receptor signaling protein activity
and protein phosphorylation pathway (SMAD9, MAPK3, and
MAP3K5). This analysis showed that the molecular interaction
differences of CARS and FARS in each subtype might be
associated with differences in the clinical outcomes of GBM
patients. Taken together, this study identified a highly inter-
connected network of aberrations, including 61 probe sets (59 PPIs
and 2 ARSs) with the down-regulated CARS and the up-regulated
FARS, which suggested that the difference of the interconnections
might have important roles in long-term survival of patients in
GBM. Thus, our results suggest potential contribution of ARSs
with their interacting gene sets on the phenotype of GBM.
Discussion
Recent evidence suggests that aminoacyl-tRNA synthetases
(ARSs) exhibit remarkable functional versatility and their non-
canonical functions have been pathologically linked to cancers.
This study demonstrates that our integrative genome-wide analysis
of ARSs shows cancer-associated activities in GBM and establishes
61 probe sets as survival signatures that are differentially expressed
in the three different prognosis subgroups in patients with GBM.
The interaction networks of CARS and FARS reveal the
molecular interaction differences of CARS and FARS in each
subtype, suggesting the potential differences in the clinical
outcomes of GBM. This work suggests higher association with
different molecular networks of an ARSs in the biology of GBM,
and may yield key biological mechanisms behind the difference of
the subtypes.
ARSs and AIMPs have been explored as therapeutic targets
against cancer by network mapping criteria and known robust
protein-protein interaction factors for most of these genesets, but
these have been neglected due to the lack of correlations of
genotype-phenotype in certain clinical situations [1]. The wide-
spread acceptance that non-conventional functions of ARSs have
been validated has spurred interest in investigating the reason that
there are many diseases associated with ARSN [17,18]. While
numerous genetic alterations have been described in ARSN
[18,19], such markers have proved to be of non-essential in
guiding disease complexities. Interestingly, recent expression
profiling studies have revealed that regulatory molecular networks
can be key factors to control tumorigenesis [1,10,20]. In the
current study, we identified potential molecular interaction
networks associated with tumor complexity as well as disease
subclasses in GBM signaling pathways.
ARSN Shows Cancer-associated Interactions
We compared the expression profiles of the genes encoding the
23 ARSN with DTGs obtained from the NCI’s cancer gene index
(CGI) and established a cancer-association map showing how
Aminoacyl-tRNA Synthetase in Glioblastoma
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much ARSs and AIMPs could be differently interacted to ten
different cancers. The strong association between ARSN and the
ten cancers is consistent with our previous findings [1]. In our
previous analysis, the 23 ARSN showed expression profiles that
are similar to those of CAGs in ten different cancer types and that
are clearly distinguishable from the pattern of nonCAGs
(combined P,0.0001). ARSN showed a high degree of association
in most of the tested cancers, except for pancreas, prostate, liver,
and gastric cancers, which was consistent with our results. Reasons
for association of ARSN with some cancer types (e.g., lymphomas,
breast) but not others (e.g., pancreatic, prostate) should be further
studied. Among the components of ARSN, in our two results, both
GARS and AIMP1 showed relatively higher cancer-associated
network, indicating their potential importance in cancer biology.
While there has been progress in understanding the role of AIMP1
in cancer [21,22], GARS functions in cancer biology have not
been defined. Several previous studies have reported GRS-
associated phenotypes that 11 distinct mutant alleles for GRS in
the human population caused CMT (Charcot–Marie–Tooth)
neuronal disease [19] and GRS upregulation in autoimmune
patients [23] and defects in GARS are the cause of distal spinal
muscular neuropathy type 5 [24]. Consistent with well-established
correlations of GRS to several diseases, we already found that
GRS proteins or fragments have activity to induce apoptosis of
cancer cells specifically. In our previous study, the GRS proteins
secreted from the macrophages was attached to cancer cells and
involved in specific anticancer activities through caspase 3
activation and MAPK inactivation [25,26]. While the current
analysis utilizes a large scale analysis, these molecules are
representative of a particular interest for new markers related to
cancer treatments.
Finding of ARSN Biology-associated Patient Subtype in
Glioblastoma
For GBM-associated systematic analyses of ARSs and AIMPs,
we performed ARSN-DTGs/PPIs/nonCAGs interaction analyses
and visualized the relationship using several correlation maps,
showing a significant positive or negative correlation between
ARSN and other two gene sets. Pearson correlation coefficient is
one of the most convenient measures to evaluate gene expression
similarities. In our data set (254 GBM affymetrix U133plus2
microarray dataset), we used enough number of dataset because
a smaller sample number tends to produce larger amplitude of
correlation values between any two genes [27]. Also we did not
integrate other dataset using public database because selection of
the GeneChip normalization method strongly affected the
performance of coexpression data. We used Pearson correlation
coefficient itself to compare each dataset and showed the
differences among the datasets statistically significant (P,0.001,
one-way ANOVA). WARS, RARS, and AIMP1 in the first group
showed highly associated correlation with 31 DTGs. While most
ARSN members in the second group showed weak correlations,
MARS in the third group was distinguished by markedly negative
correlation with the DTGs. Two highly associated groups showed
activation of ANSN and DTGs gene expression, indicative of
protein biosynthesis and cell proliferation, respectively. Previous
Figure 4. ARSN biology-dominant groups in patients with GBM. (a) We identified probe sets whose expression most strongly correlated with
survival (Kaplan-Meier plots versus survival times, log-rank t-test ,0.05). This analysis identified that 122 resulting probe sets of ARSN, DTGs, and PPIs
that were correlated with survival in patients with GBM. Then, we performed a supervised clustering with the probesets and GBM subtypes such as
proneural (PN), proliferative (Prolif) and mesenchymal (Mes). This analysis showed that 61 probeset as signature genes were differentially expressed in
the three discrete subgroups. The 61 probe sets are presented in matrix format, where rows represent individual genes and columns represent each
tissue. Each cell in the matrix represents the expression level of a gene in an individual tissue. Red and green cells reflect high and low expression
levels, respectively. (b) Tumor subgroups are distinguished by CARS and FARS. Horizontal bars denote mean values. CARS is enriched in Mes and
Prolif subgroups, while FARS in PN subgroup. Each Kaplan-Meier plot of overall survival in 130 GBM patients grouped on the basis of expression of
CARS and FARS. The difference between two groups was significant when the P value was less than 0.05. (c) Hierarchical clustering of the GSE4290
dataset of 81 GBM samples from patients with GBM and 23 non-tumor tissues based on the 61 probe sets. Each gene with an expression status were
shown in Supplementary Figure S21–S23. Nine probes were significantly overexpressed in the non-tumor samples, with 2 probes not showing in this
analysis.
doi:10.1371/journal.pone.0040960.g004
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studies have suggested the overexpression of MRS in glioma and
glioblastomas [11] but have not indicated the cause of the cancer.
Of note, WRS- and MRS-guided groups are characterized by
another signature analysis that has been associated with the
patterns of gene-class association types. In this analysis, genes
driving glioblastomas such as KRAS, NF1, MARCKS, TGFb2,
TP53, and NFKB1 were differentially correlated with three classes
of ARSN showing very similar groups to mentioned above [28–
33]. These results indicated that ARSNs suggest possible
mechanisms and processes involved in the cancer-associated
regulation of GBM biology [34].
Several clinical information such as tumor stage and grade are
powerful predictors of outcome in patients with cancers [35,36].
Although these factors do not predict survival or response to
therapy in patients with advanced disease [36], DNA microarray
analyses have identified genes whose expression levels correlated
with survival in cancers [37]. Several gene expression studies have
identified prognostic gene sets using a statistical cut-off alone, but
these genes have not been validated for more accurate diagnosis
and prognosis. To identify clinically relevant gene expression
profiles correlated with long-term survival and ARSN biology-
dominant subgroups in GBM tumors, we first identified probe sets
whose expression most strongly correlated with survival, showing
122 resulting probe sets in patients with GBM. Using well-known
glioblastoma subtypes such as PN, Prolif and Mes [15], we found
that a cluster of 61 signature genes were differentially expressed in
the three discrete subgroups. The PN subtype showed a dominant
feature of expression pattern of the 61 gene sets, while Prolif
subtype appears similar to Mes subtype. The Prolif and Mes
subtypes could appear to vary with the mere extent of expression
of these 61 signatures compared to PN subtype and not
diametrically oppositely regulated compared to 35 signature genes
as reported previously [15]. However, the 61 probe sets were
significantly correlated with survival among the 846 probe sets that
can directly interact with ARSN, and differentially expressed in
the three discrete subgroups based on the statistical cut-off
(P = 0.01). This study thus suggests that the molecular interaction
differences of ARSN in each subtype might be associated with
differences in the clinical outcomes of GBM patients. Also, a highly
interconnected network of the 61 probe sets might correlate with
the established better survival markers of the PN such as a younger
age and grade III-like histology [15]. Of note, the expression of
CARS and FARS appears to be unique to tumors of the PN
subtype. We then used the interaction networks of CARS and
FARS to explore the molecular interaction differences of CARS
and FARS in each subtype, suggesting the potential differences in
the clinical outcomes of GBM patients. Our protein interaction
network-based approach is to explore inter-connected proteins
responsible for specific cellular functions [38]. Using the PPI
networks, the identified disease-related genes could be functionally
related and reveal key biological mechanisms behind the
difference of the subtypes [39,40].
The significant association between CARS and FARS, and the
PN signature supports our classification, linking the existence of an
ARSN biology-dominant subgroup, not described in other studies.
Thus, the 61 gene signatures might correlate with the established
survival markers of the PN [41], but in this study we could not
show a clear hypothesis to explain the relationship two poor
prognosis subtypes with the signatures. Thus, further studies and
reproducible results are necessary to evaluate an ARSN biology-
dominant subgroup in the biology of GBM. Also, understanding
whether any of these targets are driver genes of aberrant tumor
growth and survival potency in GBM is a next major challenge of
our research. Taken together, our results suggest potential
contribution of ARSN with their interacting DTG and PPI gene
sets on the phenotype of GBM. Our findings provide the rational
basis for the development of new drug leads and therapeutic
concepts in the ARSN studies [42,43].
Figure 5. Molecular signatures of CARS and FARS interaction networks in patients with GBM. (a) We identified probe sets whose
expression most strongly correlated with CARS and FARS in each subtype. This analysis identified that 88 resulting probe sets of the 48 genes. Then,
we performed a supervised clustering with the probesets and GBM subtypes such as proneural (PN), proliferative (Prolif) and mesenchymal (Mes). This
analysis showed that 24 probeset as signature genes were differentially expressed in the three discrete subgroups (P = 0.001). The 24 probe sets are
presented in matrix format, where rows represent individual genes and columns represent each tissue. Each cell in the matrix represents the
expression level of a gene in an individual tissue. Red and green cells reflect high and low expression levels, respectively. (b) Tumor subgroups are
distinguished by interactors of CARS and FARS. Horizontal bars denote mean values.
doi:10.1371/journal.pone.0040960.g005
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Materials and Methods
Geneset Selection
We selected 4 different genesets, as published previously [1], to
examine the potential association of the ARSs and AIMP1–3
(together referred to as ARSN) with GBM at a systemic level.
Briefly, we used the NCI cancer gene index, a collection of records
on 6,955 human genes that were selected from Medline searches
using cancer-related disease or drug/compound terms in the NCI
Thesaurus (https://cabig.nci.nih.gov/inventory/data-resources/
cancer-gene-index). From these genes, we selected 3501 cancer-
associated genes that have been validated by manual curation, and
causal relationship to cancer. Using 11 public database showing
the curated interactions of human proteins (HPRD, BioGRID,
KEGG, Reactome, BIND, MINT, IntAct, InnateDB, DIP,
STRING, and PharmDB), we further selected 528 protein-protein
interactors with 23 ARS/AIMPs. Among those genes, we selected
124 DTGs that consistently up- or down-regulated in 43 GEO sets
(www.ncbi.nlm.nih.gov/geo) of 14 different cancer types, and 404
genes as protein-protein interactors (PPIs) of ARSs. The curated
interactions were defined as the ones identified by various assays
including yeast two hybrid and immunoprecipitation. For the
comparison, we also selected 1874 non-cancer-associated genes
(nonCAGs) that are not included in the CGI and do not show
significant cancer-associated expression profiles in 22 public
cancer datasets (P values .0.5) as reported previously [1]. These
genes may interact with ARSN but not implicated in cancer.
Glioblastoma Dataset in The Cancer Genome Atlas
To analyze the expression data, we directly accessed the input
data through TCGA Data Portal (254 GBM affymetrix U133plus2
expression array). The CEL files were re-processed using the R
statistical computing platform and packages from Bioconductor
bioinformatics software project (www.r-project.org), and a RMA
(robust multiarray average) intensity on a log-squared scale was
generated for each probe set. Two independent filters were applied
to probesets to remove low level signal intensity or not expression
in brain tissue: 1) Probesets with less than 10% ‘‘present’’ and
‘‘marginal’’ calls were removed. 2) Probesets that contains more
than 10% of accumulated zeros across samples were removed.
These steps reduced the probesets from 54,000 to 34,178 in the
set. Genes that have significantly changed can then be analyzed
further. A t-test assesses whether the means of two groups are
statistically different from each other. Then we performed
supervised hierarchical clustering based on the most variably
expressed genes using the Euclidean distance as the similarity
metric and the complete linkage method as the between-cluster
distance metric. We analyzed the functional networks using tools
from Cytoscape that is an open-source software for visualizing
molecular interaction networks [44]. To validate the data
generated by TCGA, we directly accessed another independent
public GBM gene expression datasets (GEO accession
#GSE4271) [15]. In total, 100 tumors having survival clinical
data were profiled for class discovery and survival analysis.
Survival was defined as the time interval from surgery until the
date of death.
Correlation-coefficient Map Construction
To calculate the degree of association between ARSN geneset
and other three genesets on the basis of their gene expression, we
calculated correlation coefficient as follows [45–47]; we normal-
ized each expression level of one probeset by subtracting its row-
wise mean and dividing by its row-wise standard deviation;
normalized each expression level of another probeset by subtract-
ing its row-wise mean and dividing by its row-wise standard
deviation. Then we took the inner product of the one normalized
probeset and the transpose of the normalized another probeset;
and divided each element in the resulting matrix by the number of
microarray minus one. The resulting correlation coefficient matrix
contains Pearson correlation coefficients relating an association
pattern in the ARSN expression and other three probesets
expression. Each probeset was then clustered on the basis of
Pearson correlation coefficients that related their expression
patterns across the 254 GBM tissues to the expression patterns
of ARSs over the same tissue set. We then clustered PPIs and
nonCAGs over ARSN on the basis of these correlation
coefficients. Hierarchical clustering (GENE CLUSTER v3.0)
and display programs (TREE VIEW) were used for analysis
(http://rana.stanford.edu/software). We performed unsupervised
hierarchical clustering based on the most variably expressed genes
using the Euclidean distance as the similarity metric and the
average linkage method as the between-cluster distance metric.
Supervised clustering of experimental samples was performed by
reducing the number of genes by statistical analysis.
Survival-associated Probeset Analysis
To identify probe sets whose expression most strongly correlated
with survival, samples were assigned into two groups based on the
expression of each probeset such as a low expression group and
a high expression group. We then performed Kaplan-Meier
survival analysis (Kaplan-Meier plots versus survival times, log-
rank t-test ,0.05) and estimated the survival distributions and the
log-rank test to assess the statistical significance of the differences
between the stratified survival groups using GraphPad Prism
(version 5, GraphPad Software Inc., San Diego, CA) [48]. Then,
we assigned each of the samples to three well-known glioblastoma
subtypes [15] by hierarchical clustering using the resulting
survival-associated probe sets that were selected as mentioned
above. A t-test (p,0.01) was used to identify marker genes whose
expression differed between samples in each subtype class
compared to other subtypes. For each subtype, differentially
expressed class signatures were compared to discover a degree of
difference. To verify class signatures in independent samples,
expression profiles of GBM samples were used [49] and predicted
the subtype of the samples in this validation dataset.
Pathway Analyses
Genes that showed differences in their expression levels were
selected for the different analyses (functional cluster analysis and
biological pathway analysis). To classify the pathway profiles,
functional analyses and KEGG (Kyoto Encyclopedia for Genes
and Genomes) pathway analyses (http://www.genome.jp/kegg/
pathway.html) were carried out as previously described [50,51].
To perform a KEGG analysis, differentially expressed genes of
each subtype were used for the calculation of their attribution to
pre-defined KEGG signaling pathways and analyzed by pair-wise
comparisons. The different number of genes were seen in a given
pathway. The Ingenuity Pathway Analysis software (IPA, In-
genuity Systems, Mountain View, CA) was utilized to identify
networks of interacting genes and other functional groups.
Semantically consistent pathway relationships were modeled based
on a continual, formal extraction from the public domain
literature (www.ingenuity.com/products/pathways_ knowl-
edge.html).
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Supporting Information
Figure S1 Cancer-associated interactions between ARSs
and AIMPs, and PPI. We selected 124 DTGs that can
significantly interact with 23 ARS/AIMPs, and 404 genes as PPIs
of ARSs. For the comparison, we also selected 1874 non-cancer-
associated genes (nonCAGs). Each brown node indicates each
gene of the geneset. Line indicates the co-association with ARSN.
(TIF)
Figure S2 Cancer-associated interactions between ARSs
and AIMPs, and DTGs.
(TIF)
Figure S3 Cancer-associated interactions between ARSs
and AIMPs, and nonCAGs.
(TIF)
Figure S4 Numbers of the cancer-associated interac-
tions between ARSs and each geneset. A large number of
the line based on the node of ARSN-DTGs indicates higher
association between ARSN and DTGs than ARSN-PPIs.
(TIF)
Figure S5 A cancer-association map of DTGs in brain
cancer. Using a cancer-associated interactions analysis, a cancer-
association map was established to display how much each DTG
gene could be differently interacted to ten different cancers. Each
brown node indicates each gene of the DTGs and node size
indicates the degree of cancer-dependent co-association of the
gene.
(TIF)
Figure S6 A cancer-association map of DTGs in breast
cancer.
(TIF)
Figure S7 A cancer-association map of DTGs in cervical
cancer.
(TIF)
Figure S8 A cancer-association map of DTGs in colon
cancer.
(TIF)
Figure S9 A cancer-association map of DTGs in gastric
cancer.
(TIF)
Figure S10 A cancer-association map of DTGs in
hematopoietic and lymphatic cancer.
(TIF)
Figure S11 A cancer-association map of DTGs in renal
cancer.
(TIF)
Figure S12 A cancer-association map of DTGs in liver
cancer.
(TIF)
Figure S13 A cancer-association map of DTGs in lung
cancer.
(TIF)
Figure S14 A cancer-association map of DTGs in
prostate cancer.
(TIF)
Figure S15 Histogram showing the frequency of the
correlation coefficient. The histogram was computed from the
three interaction set. Bars represent number of correlation
coefficients within the range indicated on the x-axis (P,0.001,
one-way ANOVA).
(TIF)
Figure S16 Correlation patterns of 23 ARSs and AIMPs
to PPI. Hierarchical clustering analysis showed that ARSN were
shared by two groups with 119 PPIs (FDR,0.014). 119 PPIs were
generated on a supervised hierarchical clustering analysis.
(TIF)
Figure S17 Correlation patterns of 23 ARSs and AIMPs
to PPI. Hierarchical clustering of ARSN based on the 117 DTGs
based on nonlinear association between two gene expression sets.
117 PPIs were correlated with two subgroups of ARSN.
(TIF)
Figure S18 Effect of ARSN gene expression on survival
in 254 GBM patients. Kaplan-Meier plot of overall survival in
254 GBM patients grouped on the basis of expression of each
probeset. The difference between two groups was significant when
the P value was less than 0.05.
(TIF)
Figure S19 Effect of DTG gene expression on survival in
254 GBM patients.
(TIF)
Figure S20 Effect of PPI gene expression on survival in
254 GBM patients.
(TIF)
Figure S21 Hierarchical clustering of the GSE4290
dataset. Hierarchical clustering of the GSE4290 dataset of 81
GBM samples from patients with GBM and 23 non-tumor tissues
based on the 61 probe sets. Nine probes were significantly
overexpressed in the non-tumor samples, with 2 probes not
showing in this analysis. The data are presented in matrix format
in which rows represent individual genes and columns represent
each tissue. Each cell in the matrix represents the expression level
of a gene feature in an individual tissue. Red and green in cells
reflect high and low expression levels, respectively.
(TIF)
Figure S22 Hierarchical clustering of the GSE4290
dataset of astrocytomas (II and III).
(TIF)
Figure S23 Hierarchical clustering of the GSE4290 data
set of oligodendrogliomas (II and III).
(TIF)
Table S1 Four gene sets including ARSN, DTG, PPI, and
nonCAG.
(XLS)
Table S2 Probe sets of each ARSN, DTG, PPI, and
nonCAG.
(XLS)
Table S3 31 DTG genes associated with ARSN.
(XLS)
Table S4 16 DTGs correlated with three subgroups of
ARSN.
(XLS)
Table S5 122 probe sets correlated with survival in
patients with GBM.
(XLS)
Table S6 61 probe sets among 122 probe sets.
(XLS)
Aminoacyl-tRNA Synthetase in Glioblastoma
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e40960
Table S7 48 genes that can directly interact with CARS
and FARS.
(XLS)
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